A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities ot...

Full description

Bibliographic Details

Published in:	Frontiers in oncology Vol. 9; p. 303
Main Authors:	Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 26-04-2019
Subjects:	breast cancer gene expression intrinsic subtype non-luminal Oncology PAM50 PAM50 breast cancer intrinsic subtype non-luminal gene expression
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!